Day: May 14, 2020

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it intends to offer and sell 6,000,000 shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. TG Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.TG Therapeutics intends to use the net proceeds of the public offering to fund the continued development of ublituximab and umbralisib, the potential in-license,...

ESCONDIDO, Calif., May 14, 2020 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (Nasdaq: OSS), a global leader in specialized high-performance edge computing and AI on the Fly®, reported record results for its first quarter ended March 31, 2020.First Quarter 2020 Financial and Operational HighlightsRevenue increased 33% to a record first quarter of $13.4 million.Gross profit improved to $3.4 million or 25.4% of revenue.Secured design win for new mil-spec flash storage array for airborne sensor data collection, reflecting the unique capabilities of the company’s award-winning flash array technology.Introduced new OSS PCIe Gen 4 expansion system incorporating the latest NVIDIA V100S Tensor Core GPU. This system delivers data center capabilities to HPC and AI deployments at the edge. So far in 2020, the company has received more than $3.5...

NEWTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2020 and provided an update on the Company’s recent corporate developments.“Over the last several months, we made significant progress in the expansion and further diversification of our product pipeline with the recent addition of emetine, a broad-acting and potent antiviral for the treatment of COVID-19 patients,” said Chris Schelling, CEO and Founder of Acer. “We are very pleased to be collaborating with NCATS on the development of emetine and look forward to advancing this important program....

AUSTIN, Texas, May 14, 2020 (GLOBE NEWSWIRE) — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter March 31, 2020.“Despite late first quarter challenges from COVID-19, we delivered strong first quarter revenue and test volume growth year over year. In fact, test volume was only down 5% as compared to the fourth quarter 2019. Delivering surgical triage results to physicians during this period of operation room rationing and backlog is essential,” said Valerie Palmieri, Chief Executive Officer of Vermillion.“We are starting to see patients return to their providers and test volumes rebound. OVANex and Endocheck study site recruitment also continues and we do not expect a significant delay in our product pipeline. In...

PHILADELPHIA, PA, May 14, 2020 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ:FIVE), the trend-right, high-quality extreme-value retailer for tweens, teens and beyond, today announced that it will hold its Annual Shareholder Meeting as a virtual meeting as a result of continuing concerns surrounding COVID-19. The meeting will still be held on Tuesday, June 16, 2020 at 9:00 am ET, as previously announced. Shareholders will not be able to attend the Annual Meeting physically. Shareholders are entitled to participate in the virtual Annual Meeting, post questions, and vote their shares, if they were a shareholder of record as of the close of business on April 21, 2020, the record date, or hold a legal proxy for the meeting provided by the shareholder’s bank, broker, or nominee.Attending the Annual MeetingTo attend and participate in the...

ORLANDO, Fla., May 14, 2020 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the world’s leading brands, reported its financial and operational results for the first quarter ended March 31, 2020.Q1 2020 Financial Summary Compared to Q1 2019Total revenue was the same at $4.8 million in each quarter.Managed Services revenue increased 7% to $4.1 million, compared to $3.9 million.SaaS Services revenue decreased 36% to $583,000, compared to $913,000.Total Gross Billings* decreased 22% to $6.1 million, compared to $7.8 million.Total costs and expenses were $10.9 million, compared to $6.5 million. Increase driven by a $4.3 million impairment of goodwill in Q1 2020.Net loss was $6.2 million, compared to a net loss of $1.8 million.Adjusted EBITDA* was...

BURNABY, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, May 21, 2020.  Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 8385218. The webcast will be broadcast live on the “Investors” section of Xenon’s website at www.xenon-pharma.com and will be available for replay following the call for 30 days.About Xenon Pharmaceuticals Inc.

Quarterly revenue of $3.96 billion, up 12 percent year over yearGAAP EPS of $0.82 and non-GAAP EPS of $0.89, up 17 percent and 27 percent year over year, respectivelyReturned $392 million to shareholdersSANTA CLARA, Calif., May 14, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. (NASDAQ: AMAT) today reported results for its second quarter ended Apr. 26, 2020.Second Quarter ResultsApplied generated revenue of $3.96 billion. On a GAAP basis, the company recorded gross margin of 44.2 percent, operating income of $932 million or 23.6 percent of net sales, and earnings per share (EPS) of $0.82.On a non-GAAP adjusted basis, the company reported gross margin of 44.6 percent, operating income of $976 million or 24.7 percent of net sales, and EPS of $0.89.The company returned $392 million to shareholders including $199 million in share repurchases...

Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)-COVID-19 Program-COVID-19 Compassionate Use Case Series Published in Peer Reviewed Journal--Reported 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 Under Compassionate Use Pathway--Expanded Access Protocol Approved by FDA to Treat Critical COVID-19 Patients-            -Appointed Stephen J. Gould, Ph.D. to lead Capricor’s Exosome-Based Platform Vaccine Approach Against COVID-19--To Host Conference Call and Webcast Today at 4:30 p.m. ET-LOS ANGELES, May 14, 2020 (GLOBE NEWSWIRE) — Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class...